Tasly Pharmaceutical Group Co (SHSE:600535) PEG Ratio: N/A (As of Jul. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600535 Tasly Pharmaceutical Group Co Ltd SHSE:600535
81 GF Score
Price ¥14.59
GF Value ¥15.06
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Tasly Pharmaceutical Group Co PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Tasly Pharmaceutical Group Co's PE Ratio without NRI is 19.40. Tasly Pharmaceutical Group Co's 5-Year EBITDA growth rate is -4.80%. Therefore, Tasly Pharmaceutical Group Co's PEG Ratio for today is N/A.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for Tasly Pharmaceutical Group Co's PEG Ratio or its related term are showing as below:


During the past 13 years, Tasly Pharmaceutical Group Co's highest PEG Ratio was 49.31. The lowest was 1.47. And the median was 3.06.


SHSE:600535's PEG Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.65
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


Tasly Pharmaceutical Group Co  (SHSE:600535) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


Tasly Pharmaceutical Group Co PEG Ratio Related Terms


Tasly Pharmaceutical Group Co PEG Ratio Historical Data

* Premium members only.

The historical data trend for Tasly Pharmaceutical Group Co's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tasly Pharmaceutical Group Co PEG Ratio Chart

Tasly Pharmaceutical Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PEG Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Tasly Pharmaceutical Group Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

SHSE:600535 vs ZTS, UTHR: PEG Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Tasly Pharmaceutical Group Co's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tasly Pharmaceutical Group Co PEG Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tasly Pharmaceutical Group Co's PEG Ratio distribution charts can be found below:

* The bar in red indicates where Tasly Pharmaceutical Group Co's PEG Ratio falls into.


SHSE:600535
81GF Score
Tasly Pharmaceutical Group Co Ltd SHSE:600535
PEG Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tasly Pharmaceutical Group Co PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

Tasly Pharmaceutical Group Co's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=19.401595744681/-4.80
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.

Is Tasly Pharmaceutical Group Co (SHSE:600535) Overvalued in 2026?

Based on GuruFocus' analysis, Tasly Pharmaceutical Group Co stock appears to be undervalued. The current stock price of ¥14.59 is trading 3.1% below its estimated GF Value™ of ¥15.06. GuruFocus considers Tasly Pharmaceutical Group Co to be Fairly Valued.

Key valuation signals for SHSE:600535:

  • PEG Ratio: N/A
  • GF Value™: ¥15.06 vs. price of ¥14.59 (3.1% below fair value)
  • GF Score™: 81/100 with 1 warning sign

No single metric tells the full story. See the SHSE:600535 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Tasly Pharmaceutical Group Co Business Description

Address 2 Pujihe Road East, Beichen District, Tasly TCM Garden, Tianjin, CHN, 300410
Tasly Pharmaceutical Group Co Ltd is a China-based company engaged in the manufacturing and distribution of pharmaceutical products. Its herbal medicines include Tasly Cerebral Care Granules and Tasly ICP. Its chemical medicines comprise of Ketotifen Fumarate Tablets, Thiamphenicol Capsules, Glucurolactone Tablets and Sulpiride Tablets. Some of the other products offered by the company include PharmceuticalSubstances & API, HerbalExtract, and Concentrated Herbal Granules.
81GF Score

Get the complete analysis for SHSE:600535

PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥14.59
Price
¥15.06
GF Value